{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-092528","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-07-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.212247+00:00","generated_at":"2026-05-18T09:40:49.537575+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Invivyd forms SPEAR Study Group with top researchers to test mAbs for Long COVID","bullets":["SPEAR Study Group includes Drs. Michael Peluso, Amy Proal, David Putrino; will evaluate PEMGARDA and VYD2311.","Up to 5% of Americans report Long COVID symptoms; no approved treatments exist for the condition.","PEMGARDA currently authorized only for COVID-19 prophylaxis; not approved for Long COVID treatment.","Invivyd plans FDA meeting early 3Q 2025 to discuss rapid approval pathways for COVID-19 mAbs.","Anecdotal reports suggest pemivibart may relieve Long COVID symptoms; rigorous clinical trials are planned."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-092528","json":"https://secwatch.observer/filing/0000950170-25-092528.json","markdown":"https://secwatch.observer/filing/0000950170-25-092528.md","text":"https://secwatch.observer/filing/0000950170-25-092528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/0000950170-25-092528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025092528/ivvd-20250702.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:40:49.537575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}